Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
PHARMARON Surges 12%+ After Reaching Production Co-op Agreement with Eli Lilly for Orforglipron
Recommend 1 Positive 3 Negative 2 |
||||
|
||||
|
PHARMARON (03759.HK) surged 12.6% to $20.94 in the early session of Hong Kong equity market, and peaked at $21.06 during the intraday trading session. The Company announced a production cooperation agreement with Eli Lilly and Company (LLY.US) for the first registered oral small-molecule GLP-1 receptor agonist, Orforglipron, according to PHARMARON's official Weibo account. Pursuant to the agreement, Eli Lilly is expected to invest US$200 million in PHARMARON, and support its technological capability development, with plans to further expand the cooperation scale based on future developments. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
